The 109 keywords were divided into five different groups according to the following terms: (1) “genetic implications” (PHEX, mutation, Hyp mice/Hyp mouse); (2) “management and treatment” (burosumab, phosphate, cinacalcet); (3) “pathophysiology relationships and protein related” (Dmp-1, osteopontin, sclerostin, 1,25 dihydroxyvitamin D, phosphate metabolism); (4) “complication and quality of life” (nephrocalcinosis, hyperparathyroidism); and (5) “clinical and analytical manifestations relationship” (hypophosphatemia, Rickets, Osteomalacia, phosphaturia). This evidence concerns the gene SPP1 and nephrocalcinosis.